Consider alternatives to value-based pricing, says 2020health
Pharmaceutical companies should be allowed to continue to fix their own prices for individual drugs, according to a new report from 2020health.
The independent health think tank report “Value-based pricing: the wrong medicine for the nation?” surveyed public concerns about proposed value-based pricing. Barbara Arzymanow, main author of the report, concluded that “patients could mistake value-based pricing for a commitment to make more medicines available, which is not the case”.
The report claims that medicines pricing can be improved and urges the Government to consider alternative solutions, including continuing to allow drug companies to fix prices for individual drugs, lowering the price of older drugs to accommodate high enough prices for new products, developing a pricing system to encourage companies not to overlook rarer diseases in search of drugs for more lucrative markets and encouraging more patient access schemes to help make drugs available on the NHS.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11121106
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com